ASCO GU 2020

Complete Coverage

Combination Therapy for Advanced Urothelial Carcinoma Shows Promise in Early Clinical Trial

A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.

Genetic Counseling for Prostate Cancer May Be an Opportunity to Promote Healthy Lifestyle Approaches

Age, BMI, and education may indicate physical activity levels in men seeking genetic counseling and/or testing for prostate cancer.

Targeted Assessments May Be Needed for Some Patients With Localized Renal Cell Carcinoma

Assessments and interventions for younger and female patients with RCC may need to be targeted, as these patients may have a greater fear of disease recurrence.

Screening for Frailty May Improve Outcomes for Older Patients With Genitourinary Malignancies

The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.

Psychological Effect of an Early Prostate Cancer Diagnosis May Be Underappreciated

Findings of a prospective study demonstrated that the psychological impact of a cancer diagnosis can be significant even with cancers that have a good prognosis.

Use of Palliative Care in Managing Genitourinary Malignancies May Vary Across the United States

Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.

Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms

In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.

Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real World Setting

In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.

Metastasectomy Found to Prolong Survival in Selected mRCC Cases

In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.

Preoperative Bone Metastases Not Prognostic in mRCC

Bone metastases less predictive in the setting of cytoreductive nephrectomy.